...
首页> 外文期刊>American Journal of PharmTech Research >Formulation and Development of Environmentally Responsive Ophthalmic In-Situ Gel For Brimonidine Tartrate
【24h】

Formulation and Development of Environmentally Responsive Ophthalmic In-Situ Gel For Brimonidine Tartrate

机译:酒石酸溴莫尼定对环境敏感的眼用原位凝胶的研制与开发

获取原文
   

获取外文期刊封面封底 >>

       

摘要

ABSTRACT A major problem in ocular therapeutics is the attainment of optimal drug concentration at the site of action, which is compromised mainly due to precorneal loss resulting in only a small fraction of the drug being ocularly absorbed. Brimonidine tartrate is an antiglaucomic agent which shows rapid precorneal exclusion and reduced ocular bioavailability when given in form of conventional ophthalmic formulations. The poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions may be overcome by the use of in-situ gel forming ophthalmic systems that are instilled as drops into the eye and undergo a sol–gel transition in the cul-de-sac. In the present study, environmentally responsive ophthalmic drug delivery system composed of two gelling polymers with different phase transition mechanisms was developed. Combination of polyacrylic acid (carbopol 934P) and xanthan gum was investigated as ophthalmic vehicle. Different ratios of these polymers were used to prepare environmentally responsive ophthalmic drug delivery system by simple mixing procedure. Developed formulation was assessed for various evaluation parameters such as appearance/clarity, pH, gelation, drug content, rheological measurement, in-vitro release, and sterility testing and stability study. Prepared formulation showed agreeable appearance/clarity, acceptable pH and good gelation property. In-vitro studies demonstrated adequate drug content, desired rheological behaviour and reasonable in-vitro drug release property. Formulation was stable over one month period. In conclusion, the optimum concentration of polymers results in minimized drug loss and sustained drug release. On the basis of these findings, prepared in-situ gel may be considered as a viable alternative to conventional brimonidine tartrate eye drops. Keywords: carbopol 934P, xanthan gum, brimonidine tartrate, antiglaucomic
机译:摘要眼部治疗中的主要问题是在作用部位达到最佳药物浓度,这主要是由于角膜前损失导致仅一小部分药物被眼部吸收而受到损害。酒石酸溴莫尼定是一种抗青光眼药,当以常规眼科制剂的形式给药时,会表现出快速的角膜前排斥和降低的眼生物利用度。常规眼科解决方案所表现出的不良生物利用度和治疗反应,可以通过使用原位形成凝胶的眼科系统来克服,该系统以滴入的方式滴入眼内,并在死腔内发生溶胶-凝胶转变。在本研究中,开发了由具有不同相变机理的两种胶凝聚合物组成的环境响应性眼科药物递送系统。研究了聚丙烯酸(carbopol 934P)和黄原胶的组合作为眼用载体。通过简单的混合程序,将不同比例的这些聚合物用于制备对环境敏感的眼科药物递送系统。对开发的制剂进行各种评估参数的评估,例如外观/澄清度,pH,凝胶化,药物含量,流变学测量,体外释放,无菌测试和稳定性研究。制备的制剂显示出令人满意的外观/澄清度,可接受的pH和良好的胶凝性质。体外研究表明足够的药物含量,所需的流变行为和合理的体外药物释放特性。配方在一个月内稳定。总之,聚合物的最佳浓度可最大程度减少药物损失和持续释放药物。基于这些发现,可以将原位制备的凝胶视为常规酒石酸溴莫尼定滴眼液的可行替代品。关键词:卡波姆934P,黄原胶,酒石酸溴莫尼定,抗青光眼

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号